Dr. Richard Massey is retiring as president and chief operating officer of BioVeris (Gaithersburg, Maryland), effective Aug. 1. Massey will remain on the board of directors. In recognition of his contributions to the company, BioVeris is naming its research and development facility after Massey. CEO Samuel Wohlstadter will assume Massey's responsibilities. BioVeris is developing technologies in diagnostics and vaccines.

Boston Life Sciences (Boston), focused on the development of biopharmaceutical products for the diagnosis and treatment of central nervous system diseases, named new members to its management team: Kenneth Rice Jr., executive vice president of finance and administration, CFO and in-house counsel; Noel Cusack, PhD, senior vice president of preclinical development; Pamela McDonough, corporate controller; and Lee Summers, director of quality systems. Most recently, Rice served as vice president, CFO and chief commercial officer of Aderis Pharmaceuticals. Cusack was a founder and chief scientific officer of Aderis Pharmaceuticals and maintains a faculty position as adjunct professor of pharmacology at the University of California, Irvine. McDonough most recently was corporate controller of Aderis Pharmaceuticals. Summers was associate director of quality assurance and project management at the Harvard Gene Therapy Initiative.

Monte Wiltse has joined Fujirebio Diagnostics (FDI; Malvern, Pennsylvania) as vice president of sales and marketing. Wiltse previously held several senior-level marketing management positions with Bayer Diagnostics, where he was responsible for molecular testing systems and the oncology immunoassay reagent product line. FDI specializes in the clinical development, manufacturing and commercialization of in vitro diagnostic products for the management of human disease states, with an oncology focus.

Nancy Sousa, president of the U.S. subsidiary of Given Imaging (Yokneam, Israel), has resigned to pursue other interests. Sousa joined Given in 2002. The company said that a search is under way for an executive to lead its next phase of growth. In the interim, Gavriel Meron, president and CEO of Given, will oversee operations of the U.S. subsidiary. Given is the developer of the PillCam video capsules for detecting gastrointestinal disorders.

Jill Smith and Heather Amar are joining PRA Inter-national (Reston, Virginia), a global clinical research organization. Smith is director, corporate communications, responsible for investor and media relations as well as internal communications, while Amar will be manager, new business strategic marketing. Smith most recently served as a managing director in the Nasdaq Stock Market's corporate client group and prior to that as corporate communications director at The Medicines Company. Amar comes to PRA from the strategic alliances group at Pfizer.